1. Home
  2. STRO vs AVIR Comparison

STRO vs AVIR Comparison

Compare STRO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STRO
  • AVIR
  • Stock Information
  • Founded
  • STRO 2003
  • AVIR 2012
  • Country
  • STRO United States
  • AVIR United States
  • Employees
  • STRO N/A
  • AVIR N/A
  • Industry
  • STRO Biotechnology: Biological Products (No Diagnostic Substances)
  • AVIR Medicinal Chemicals and Botanical Products
  • Sector
  • STRO Health Care
  • AVIR Health Care
  • Exchange
  • STRO Nasdaq
  • AVIR Nasdaq
  • Market Cap
  • STRO 172.8M
  • AVIR 247.5M
  • IPO Year
  • STRO 2018
  • AVIR 2020
  • Fundamental
  • Price
  • STRO $1.95
  • AVIR $3.42
  • Analyst Decision
  • STRO Strong Buy
  • AVIR Hold
  • Analyst Count
  • STRO 7
  • AVIR 1
  • Target Price
  • STRO $12.14
  • AVIR $6.88
  • AVG Volume (30 Days)
  • STRO 1.4M
  • AVIR 556.5K
  • Earning Date
  • STRO 11-13-2024
  • AVIR 02-26-2025
  • Dividend Yield
  • STRO N/A
  • AVIR N/A
  • EPS Growth
  • STRO N/A
  • AVIR N/A
  • EPS
  • STRO N/A
  • AVIR N/A
  • Revenue
  • STRO $160,955,000.00
  • AVIR N/A
  • Revenue This Year
  • STRO N/A
  • AVIR N/A
  • Revenue Next Year
  • STRO N/A
  • AVIR N/A
  • P/E Ratio
  • STRO N/A
  • AVIR N/A
  • Revenue Growth
  • STRO 230.90
  • AVIR N/A
  • 52 Week Low
  • STRO $1.70
  • AVIR $2.75
  • 52 Week High
  • STRO $6.13
  • AVIR $4.60
  • Technical
  • Relative Strength Index (RSI)
  • STRO 37.11
  • AVIR 62.36
  • Support Level
  • STRO $1.80
  • AVIR $3.19
  • Resistance Level
  • STRO $2.01
  • AVIR $3.32
  • Average True Range (ATR)
  • STRO 0.16
  • AVIR 0.12
  • MACD
  • STRO 0.03
  • AVIR 0.04
  • Stochastic Oscillator
  • STRO 37.18
  • AVIR 94.78

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: